Gamze Guney Eskiler1, Gulsah Cecener2, Unal Egeli2, Berrin Tunca2. 1. Department of Medical Biology, Faculty of Medicine, Sakarya University, Sakarya, Turkey. gamzeguney@sakarya.edu.tr. 2. Department of Medical Biology, Faculty of Medicine, Uludag University, Bursa, Turkey.
Abstract
PURPOSE: The purpose of the study was to produce BMN 673 loaded solid lipid nanoparticles (SLNs) to improve its therapeutic index, to minimize toxicity and to overcome homologous recombination (HR)-mediated resistance. METHODS: Firstly, BMN 673-SLNs were characterized using Nano Zeta Sizer. After treatment with different concentrations of BMN 673 and BMN 673-SLNs, cell viability of HCC1937(BRCA1-/-), HCC1937-R (BMN 673-resistant) TNBC and MCF-10A normal human mammary breast epithelial cell line was analyzed by WST-1 assay. In an attempt to assess the therapeutic synthetic lethality efficacy of SLNs formulation, cell cycle arrest, DNA damage, mRNA expression levels of PARP1, H2AFX, RAD51 and BRCA1 gene were investigated. Then, PARP, ɣH2AX, RAD51 and BRCA1 protein expression and nuclear localization were analyzed by western blot and immunofluorescence analysis. RESULTS: When compared with BMN 673, BMN 673-SLNs showed remarkably a decrease in HCC1937 and HCC1937-R cells with less damage to MCF-10A cells. BMN 673-SLNs significantly induced toxicity through double-stranded DNA breaks, G2/M cell cycle arrest and PARP cleavage in TNBC cells. Additionally, BMN 673-resistance was mediated by miR-107, miR-193b and miR-1255b targeting BRCA1 and RAD51 in HCC1937 and HCC1937-R cells. However, BMN 673-SLNs treatment could overcome HR-mediated resistance in TNBC cells. CONCLUSIONS: As a result, our findings suggest that SLNs formulation strongly provides a synthetic lethal therapeutic potential in BRCA1 mutated sensitive and resistant TNBC cells.
PURPOSE: The purpose of the study was to produce BMN 673 loaded solid lipid nanoparticles (SLNs) to improve its therapeutic index, to minimize toxicity and to overcome homologous recombination (HR)-mediated resistance. METHODS: Firstly, BMN 673-SLNs were characterized using Nano Zeta Sizer. After treatment with different concentrations of BMN 673 and BMN 673-SLNs, cell viability of HCC1937(BRCA1-/-), HCC1937-R (BMN 673-resistant) TNBC and MCF-10A normal human mammary breast epithelial cell line was analyzed by WST-1 assay. In an attempt to assess the therapeutic synthetic lethality efficacy of SLNs formulation, cell cycle arrest, DNA damage, mRNA expression levels of PARP1, H2AFX, RAD51 and BRCA1 gene were investigated. Then, PARP, ɣH2AX, RAD51 and BRCA1 protein expression and nuclear localization were analyzed by western blot and immunofluorescence analysis. RESULTS: When compared with BMN 673, BMN 673-SLNs showed remarkably a decrease in HCC1937 and HCC1937-R cells with less damage to MCF-10A cells. BMN 673-SLNs significantly induced toxicity through double-stranded DNA breaks, G2/M cell cycle arrest and PARP cleavage in TNBC cells. Additionally, BMN 673-resistance was mediated by miR-107, miR-193b and miR-1255b targeting BRCA1 and RAD51 in HCC1937 and HCC1937-R cells. However, BMN 673-SLNs treatment could overcome HR-mediated resistance in TNBC cells. CONCLUSIONS: As a result, our findings suggest that SLNs formulation strongly provides a synthetic lethal therapeutic potential in BRCA1 mutated sensitive and resistant TNBC cells.
Authors: Shawn F Johnson; Cristina Cruz; Ann Katrin Greifenberg; Sofia Dust; Daniel G Stover; David Chi; Benjamin Primack; Shiliang Cao; Andrea J Bernhardy; Rhiannon Coulson; Jean-Bernard Lazaro; Bose Kochupurakkal; Heather Sun; Christine Unitt; Lisa A Moreau; Kristopher A Sarosiek; Maurizio Scaltriti; Dejan Juric; José Baselga; Andrea L Richardson; Scott J Rodig; Alan D D'Andrea; Judith Balmaña; Neil Johnson; Matthias Geyer; Violeta Serra; Elgene Lim; Geoffrey I Shapiro Journal: Cell Rep Date: 2016-11-22 Impact factor: 9.423
Authors: Ponnari Gottipati; Barbara Vischioni; Niklas Schultz; Joyce Solomons; Helen E Bryant; Tatjana Djureinovic; Natalia Issaeva; Kate Sleeth; Ricky A Sharma; Thomas Helleday Journal: Cancer Res Date: 2010-06-15 Impact factor: 12.701
Authors: Louise J Barber; Shahneen Sandhu; Lina Chen; James Campbell; Iwanka Kozarewa; Kerry Fenwick; Ioannis Assiotis; Daniel Nava Rodrigues; Jorge S Reis Filho; Victor Moreno; Joaquin Mateo; L Rhoda Molife; Johann De Bono; Stan Kaye; Christopher J Lord; Alan Ashworth Journal: J Pathol Date: 2013-02 Impact factor: 7.996
Authors: Yuko Nakagawa; Anna S Sedukhina; Naoki Okamoto; Satoi Nagasawa; Nao Suzuki; Tomohiko Ohta; Hiroyoshi Hattori; Marta Roche-Molina; Ana J Narváez; Anand D Jeyasekharan; Juan A Bernal; Ko Sato Journal: Oncotarget Date: 2015-02-28
Authors: Ashleigh Herriott; Susan J Tudhope; Gesa Junge; Natalie Rodrigues; Miranda J Patterson; Laura Woodhouse; John Lunec; Jill E Hunter; Evan A Mulligan; Michael Cole; Lisa M Allinson; Jonathan P Wallis; Scott Marshall; Evelyn Wang; Nicola J Curtin; Elaine Willmore Journal: Oncotarget Date: 2015-12-22
Authors: Simran Deep Kaur; Dinesh Kumar Chellappan; Alaa A Aljabali; Murtaza Tambuwala; Kamal Dua; Deepak N Kapoor Journal: Med Oncol Date: 2022-09-30 Impact factor: 3.738
Authors: Di Zhang; Paige Baldwin; Ana S Leal; Sarah Carapellucci; Srinivas Sridhar; Karen T Liby Journal: Theranostics Date: 2019-08-14 Impact factor: 11.556
Authors: Ramya Ambur Sankaranarayana; Alexandru Florea; Susanne Allekotte; Andreas T J Vogg; Jochen Maurer; Laura Schäfer; Carsten Bolm; Steven Terhorst; Arno Classen; Matthias Bauwens; Agnieszka Morgenroth; Felix M Mottaghy Journal: EJNMMI Res Date: 2022-09-14 Impact factor: 3.434
Authors: Zally Torres-Martinez; Yamixa Delgado; Yancy Ferrer-Acosta; Ivette J Suarez-Arroyo; Freisa M Joaquín-Ovalle; Louis J Delinois; Kai Griebenow Journal: Cancer Drug Resist Date: 2021-03-19